Antibodies to phospho ret tyr905

Manufactured by Cell Signaling Technology

Sourced in United States

Antibodies to phospho-RET(Tyr905) are laboratory reagents that specifically recognize the phosphorylated form of the RET protein at tyrosine residue 905. These antibodies can be used to detect and quantify the levels of activated RET in various experimental systems.

Automatically generated - may contain errors

Lab products found in correlation

Cleaved parp, by Cell Signaling Technology (2 mentions) Anti flag antibody, by Merck Group (1 mentions) Anti β actin antibody, by Merck Group (1 mentions) Phospho erk1 2, by Cell Signaling Technology (1 mentions) Vandetanib, by Selleck Chemicals (1 mentions) Cabozantinib, by Selleck Chemicals (1 mentions) Lenvatinib, by Selleck Chemicals (1 mentions) Anti cytokeratin antibody, by Agilent Technologies (1 mentions) Ponatinib, by LC Laboratories (1 mentions)

2 protocols using antibodies to phospho ret tyr905

RET Inhibitor Protein Expression Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

Selpercatinib and pralsetinib were from Chemietek (Indianapolis, IN, USA). Antibodies to phospho-RET(Tyr905) (#3221, 1:1000 dilution), RET (#14698, 1:1000 dilution), phospho-ERK1/2 (#4376, 1:1000 dilution), and cleaved-PARP (#9541, 1:1000 dilution) were from Cell Signaling Technology (Danvers, MA, USA). Anti-total ERK1/2 antibody (#SC-514302, 1:500 dilution) was from Santa Cruz Biotech. Anti-Flag antibody (#F1804, 1:1000 dilution), and anti-β-actin antibody (#A5316, 1:80000 dilution) was from Sigma.

Shen T., Hu X., Liu X., Subbiah V., Mooers B.H, & Wu J. (2021). The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib. NPJ Precision Oncology, 5, 48.

+ Open protocol

+ Expand

Analyzing RET and Apoptosis Signaling

Check if the same lab product or an alternative is used in the 5 most similar protocols

Antibodies to phospho-RET(Tyr905) and cleaved-PARP were from Cell Signaling Technology, antibodies to Flag-tag and β-actin were from Sigma, anti-RET antibody was from Santa Cruz Biotech. Anti-TTF1 (ab137061) antibody was from Abcam. Anti-cytokeratin antibody was from Dako (cat. No. Z0622). Ponatinib was from LC Laboratories. Cabozantinib, vandetanib, and lenvatinib were from Selleckchem.

Huang Q., Schneeberger V.E., Luetteke N., Jin C., Afzal R., Budzevich M.M., Makanji R.J., Martinez G.V., Shen T., Zhao L., Fung K.M., Haura E.B., Coppola D, & Wu J. (2016). Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma. Molecular cancer therapeutics, 15(10), 2521-2529.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!